UNCTAD Official: Need For Policy Coherence In Local Pharmaceutical Production 17/07/2015 by Ani Mamikon for Intellectual Property Watch and Rishi Dhir for Intellectual Property Watch Leave a Comment Despite progress in recent years to boost local pharmaceutical production in developing countries, policy coherence across the countries is lacking, according to an official at the United Nations Conference on Trade and Development (UNCTAD).
Learning From Ebola 14/07/2015 by Intellectual Property Watch 1 Comment In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding. Because he was initially believed to have malaria, Lokela was given quinine, but his symptoms got worse and he soon died. Shortly afterwards, those who had been in contact with Lokela also died. … Almost four decades later, there is still no cure for Ebola, despite the fact that drug development on average takes about a third of this time frame, write William Fisher and Quentin Palfrey.
Paper: Commons Approach To European Knowledge Policy Could Yield Better Outcomes 09/07/2015 by Ani Mamikon for Intellectual Property Watch and Rishi Dhir for Intellectual Property Watch Leave a Comment A new paper released earlier this month finds that the commons perspective, which embraces knowledge as a shared resource and its management a joint responsibility, could contribute to EU policy discussions and yield better policy outcomes in areas such as health, environment, science and culture, and the internet.
Secret Regional Comprehensive Economic Partnership (RCEP) Takes Centre Stage In Asia 24/06/2015 by Patralekha Chatterjee for Intellectual Property Watch 4 Comments The Trans-Pacific Partnership (TPP), part of US President Barack Obama’s promised pivot to Asia, has stirred up a hornet’s nest on the ethics of trying to hammer out a trade deal in secrecy. But it is not the only one. A proposed trade agreement in Asia, the Regional Comprehensive Economic Partnership (RCEP), is facing the same hiccups and flak.
LDC Pharma Extension Request At WTO Yields Support But Needs Further Discussion 11/06/2015 by Catherine Saez, Intellectual Property Watch 2 Comments World Trade Organization members this week could not decide on a request from least-developed countries to extend a waiver allowing them to forego the enforcement of intellectual property rights on pharmaceutical products until their economies are stronger. Discussions are expected to be conducted informally until the next meeting of the organisation’s council on IP rights in October.
US Shifts Stance On Drug Pricing In Pacific Trade Pact Talks, Document Reveals 10/06/2015 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment From the New York Times: WASHINGTON — Facing resistance from its Pacific trading partners, the Obama administration is no longer demanding protection for pharmaceutical prices under the 12-nation Trans-Pacific Partnership, according to a newly leaked “transparency” annex of the proposed trade accord. But American negotiators are still pressing participating governments to open up the process that sets reimbursement rates for drugs and medical devices. Public health professionals, generic drugmakers and activists opposed to the trade deal, which is still being negotiated, contend that it will empower big pharmaceutical firms to command higher reimbursement rates in the United States and abroad, at the expense of consumers.
IP Key For Financing Innovation, Speakers Say At WTO 10/06/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment Intellectual property protection is vital to finance innovation and in particular for start-ups, according to speakers at an event co-organised this week by the European Union, Switzerland, and the United States at the World Trade Organization.
Climate Change Headlines G7; Merkel Commits To Conclude TTIP During Obama’s Term 09/06/2015 by Monika Ermert for Intellectual Property Watch Leave a Comment MUNICH — The agreement of the heads of states of the United States, Canada, Japan, United Kingdom, France, Italy and Germany to reduce global warning to less than two degrees made the biggest headlines of the G7 Summit on Elmau Castle, Germany, in the Bavarian Alps. Also agreed were commitments on trade and on public health, including research and development for neglected diseases.
Confidential USTR Emails Show Close Industry Involvement In TPP Negotiations 05/06/2015 by William New, Intellectual Property Watch 45 Comments While a full range of stakeholders would be affected by the outcome of the Trans-Pacific Partnership (TPP) agreement under secret negotiation by the United States and a dozen trading partners, corporate representatives have had a special seat at the negotiating table, as shown by hundreds of pages of confidential emails from the US Trade Representative’s office obtained by Intellectual Property Watch. The emails give a rare and fascinating perspective on how policy is developed in the trade office.
Alternative Summit Offers Ideas For Trade Agreements, G7, Amid 40,000 Protesters 05/06/2015 by Monika Ermert for Intellectual Property Watch 4 Comments MUNICH — Just days before leaders of the Group of 7 (G7) industrialised countries gather in the well-guarded Bavarian Castle Elmau, a broad coalition of organisations invited free trade critics to an International Summit for Alternatives in Munich. Speaking there, Jean Ziegler, well-known former UN rapporteur for the right to food, shrugged off the possible effects of the G7 Summit.